Evonik's Fork in the Road: A €24 Bid, an Ashland Probe, and Nothing Signed
Published on 10/25/2026 at 18:31 | Editorial boerse-global.de
Evonik investors woke Friday to a 3.4% share-price gain, but the advance rests on a report, not a contract. Reuters, citing people familiar with the talks, said BASF lifted its offer for the Essen-based specialty chemicals group from €22.15 to €24 per share — a valuation of roughly €11.18 billion. Neither company has confirmed the figure, and Evonik, BASF and the RAG-Stiftung all declined to comment.
The bid is only half the story. On the same day, Handelsblatt reported that Evonik has for some time been weighing larger acquisitions outside Europe, with a possible takeover of U.S. specialty chemicals firm Ashland in focus. That review is at an early stage, and no deal is assured. Evonik, as a matter of policy, does not comment on market rumors.
Buyer or target — two roles, one valuation question
The two strands put shareholders in an unusual position. In one scenario Evonik is the acquirer; in the other it is the acquired. Each path deserves its own assessment. An early-stage acquisition review proves neither that a purchase will happen nor that Evonik has turned its back on BASF. By the same token, a higher offer price is not the same as an agreed takeover — Reuters reported that Evonik will examine the bid, nothing more.
What BASF has put on the table goes beyond euros per share. Chief executive Markus Kamieth, speaking Thursday according to Reuters, paired the approach with commitments: no compulsory redundancies before 2032, and collective bargaining agreements and social partnership left untouched. Those pledges shift attention to the terms of any combination — employment and existing agreements alongside price. They do not substitute for a signed agreement.
Should investors sell immediately? Or is it worth buying Evonik?
The gap between headlines and hard decisions
The pivotal issue is the move from reported deliberations to confirmed corporate decisions. Neither the Ashland review nor the sweetened BASF bid yet allows a reliable call on which route will actually be taken. A reported offer price is not a guaranteed proceeds figure, and an early acquisition review cannot be booked as added enterprise value. A defensible assessment requires concrete decisions and their conditions.
That distinction matters because Friday's rally was tied to the report of the higher BASF bid. Should confirmation fail to materialize, that support could erode. Ashland offers no assured counterweight either: the review is early, completion uncertain. If Evonik walks away from that path, no agreed transaction will have collapsed — but a hoped-for strategic option would disappear. A concrete acquisition, conversely, would not automatically be a positive; shareholders would need to weigh its terms and industrial logic. A shift from takeover hope to self-directed deal changes the valuation question rather than settling it.
What a clearer picture would require
Greater clarity is the starting point for the brighter scenario. If the BASF offer is confirmed and concrete negotiations follow, the valuation could anchor more firmly to a transaction actually being pursued — Reuters describes the higher bid as an attempt to prompt takeover talks. A more defined Ashland review, meanwhile, could show which alternative Evonik is charting itself, with the economic rationale and deal terms the key items. A favorable outcome does not demand that both ventures proceed; it demands that a coherent strategy emerge from the competing options. The two paths must not be added together as though they were already secured contributions to value.
Evonik at a turning point? This analysis reveals what investors need to know now.
Until then, the stock's framing hinges on how far each option has been confirmed. The next scheduled checkpoint is Evonik's third-quarter 2026 report on November 3 — a fixed reference point for operating performance, though no decision on BASF or Ashland has been announced. The quarterly figures can sharpen the economic basis of the valuation. Direction, however, will be set by confirmed steps, not by the number of possible deals in play.
Ad
Evonik Stock: New Analysis - 25 October
Fresh Evonik information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
